Thomas Myers, MD
Pain Medicine · Mandeville, LANPI 1881973956
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 66.4% of it on its own, with 48 other manufacturers making up the rest. Reporting peaked in 2023 at $37,396 and has fallen 87.7% since, to $4,584 in 2025. Among pain medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $267.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$79K
- SPR Therapeutics, Inc$16K
- Spinal Simplicity, LLC$9K
- Foundation Fusion Solutions, LLC$6K
- Medtronic$4K
- Relievant Medsystems, Inc.$1K
- plus $3K from 43 others
Across 7 payments — averaging $7808.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mesoblast, Inc.$48K
- Foundation Fusion Solutions, LLC$7K
What the payments were for
- Consulting fees$21,13518%
- Speaking & faculty fees$69,82059%
- Travel & lodging$9,9338%
- Food & beverage$12,30610%
- Education$5,1134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERION$20,255
- WaveWriter Alpha Prime 16$18,393
- SPRINT PNS System$15,691
- Superion Indirect Decompression System$14,676
- HA MINUTEMAN G3-R$9,035
- VERIFLEX$5,390
- SPECTRA WAVEWRITER$3,423
- SYNCHROMEDII$2,741
- GENERAL - THERAPIES$2,000
- Intracept$1,605
- WAVEWRITER ALPHA$1,348
- INTELLIS ADAPTIVESTIM$467
- Nalu Neurostimulation System$379
- Proclaim IPG$162
- ETERNA$139
- GENERAL PAIN MANAGEMENT$136
- CLINICAL TRIAL PRODUCT$117
How this compares
$118,308 in reported general payments places this provider in the 95th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 34 | $29,786 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 540 | $16,099 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 860 | $14,097 |
| MovantikNaloxegol Oxalate | 28 | $11,324 |
| OxycontinOxycodone Hcl | 21 | $9,552 |
| Oxycodone Hcl | 235 | $5,502 |
| Gabapentin | 416 | $4,265 |
| Pregabalin | 254 | $2,438 |
| Fentanyl | 11 | $1,884 |
| Tizanidine Hcl | 134 | $1,659 |
| Duloxetine Hcl | 109 | $1,409 |
| Tramadol Hcl | 237 | $1,303 |
| Diclofenac Sodium | 22 | $1,253 |
| Morphine Sulfate ErMorphine Sulfate | 61 | $1,114 |
| Lidocaine | 20 | $961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $40 | $29,78634 claims |
| Redhill Biopharma Inc.Movantik | $13 | $11,32428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 pain medicine providers in Louisiana.
Other pain medicine in Mandeville
- Alan KayeNew Orleans$76K
- Derrick DeanTerrytown$68K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Gassan ChaibanLake Charles$30K
- Yashar EshraghiNew Orleans$22K
- Prathima AnandiShreveport$19K
- Jason GremillionBaton Rouge$19K
- Eric StockwellMetairie$18K
- Aaron Hanyu-DeutmeyerNew Orleans$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.